In:
Chemical Biology & Drug Design, Wiley, Vol. 82, No. 5 ( 2013-11), p. 500-505
Abstract:
The first example of an inhibitor of the kinase TAK 1 that binds in the DFG ‐out conformation is disclosed. These preliminary studies used kinase‐targeted screening and structure‐based drug design to create a molecule with dual pharmacological inhibition of p38 and TAK 1 that demonstrated significant activity in a cell‐based, anti‐inflammatory assay.
Type of Medium:
Online Resource
ISSN:
1747-0277
,
1747-0285
DOI:
10.1111/cbdd.2013.82.issue-5
Language:
English
Publisher:
Wiley
Publication Date:
2013
detail.hit.zdb_id:
2216600-2
SSG:
12
Bookmarklink
